Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Macitentan/Tadalafil vs PrOpsynvi in Healthy Males
NCT06553937Phase 1Completed
- Sponsor
- Humanis
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Humanis. Primary endpoints: Maximum Concentration at 72 hours and Area Under the Curve (0-t) at 72 hours. Started May 2024; status: completed.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06553937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553937.